Regulatory changes
2 regulatory changes appeared in Japan during Week 17, 2026. Regulatory-change activity should be checked against PMDA requirements, guidance, and downstream compliance workflows.
Japan medical device regulatory intelligence, Week 17, 2026.
Signals from 2026-04-20 to 2026-04-26, covering safety alerts, regulatory changes, device registrations, market movement, and source activity for Japan.
Signals
5
Sources
3
Index status
Indexable
EXECUTIVE SUMMARY
Japan generated 5 qualifying medical device signals during Week 17, 2026. Regulatory changes led the week with 2 signals, while Nikkei Asia was the most active source. BYD reports earnings, impacting the financial landscape in key markets including Asia Pacific. The FDA issued a Class I recall for the Automated Impella Controller due to detection issues with the Impella pump.
Key observations
Regulatory changes accounted for 2 of 5 qualifying signals, making it the main review lane for the week.
Market signals formed the second-largest cluster, which is useful context for teams separating safety work from regulatory and market monitoring.
Nikkei Asia contributed 2 signals, so source-level follow-up should start there.
FDA appeared repeatedly in the highlighted signals, which may warrant closer product, manufacturer, or competitor tracking.
Category interpretation
Market signals
1 market signals appeared in Japan during Week 17, 2026. Market signals help connect regulatory monitoring with launch planning, reimbursement, and commercial strategy.
Safety alerts
1 safety alerts appeared in Japan during Week 17, 2026. Safety concentration usually matters to quality, vigilance, and post-market surveillance teams because it can reveal emerging field risks.
Competitor moves
1 competitor moves appeared in Japan during Week 17, 2026. Competitor-linked activity is most useful when paired with product codes, indication context, and adjacent safety signals.
Recommended monitoring focus
- Review PMDA safety and recall activity for product categories that overlap your portfolio.
- Check whether new Japan regulatory changes affect submission, labeling, vigilance, or post-market workflows.
- Review competitor-linked signals for launch timing, market access movement, and product category momentum.
- Use market trend signals to brief commercial, strategy, and market access teams alongside regulatory stakeholders.
Source-backed signal evidence
These source-linked items support the weekly analysis above. They are included for verification and follow-up, not as a raw feed export.
Nikkei Asia·Market signals·
BYD earnings, Japanese airline financials, Genting's New York casino tables
BYD reports earnings, impacting the financial landscape in key markets including Asia Pacific.
SourceFDA Warning Letters·Safety alerts·
FDA Class I: Automated Impella Controller (AIC), used in left heart support blood pump, including the following: 1. Impella Controller, Packaged, AU; Product Code: 0042-0000-AU. 2. Impella Controller, Pack (Abiomed, Inc.)
The FDA issued a Class I recall for the Automated Impella Controller due to detection issues with the Impella pump.
SourceFDA Device Registration & Listing·Regulatory changes·
FDA Registration: JAPAN GAS COMPANY LIMITED (3010188783)
Japan Gas Company Limited has registered a medical device with the FDA under product code FCG.
SourceFDA Device Registration & Listing·Regulatory changes·
FDA Registration: OMRON HEALTHCARE Co., Ltd. Matsusaka Factory (9611045)
OMRON HEALTHCARE's Matsusaka Factory has registered product code DXN with the FDA.
SourceNikkei Asia·Competitor moves·
How security concerns derailed MBK's bid for Japan's Makino Milling
Security concerns halted MBK's acquisition of Makino Milling in Japan due to regulatory issues.
SourceRegulatory changes
FDA Device Registration & Listing·Regulatory changes·
FDA Registration: JAPAN GAS COMPANY LIMITED (3010188783)
Japan Gas Company Limited has registered a medical device with the FDA under product code FCG.
SourceFDA Device Registration & Listing·Regulatory changes·
FDA Registration: OMRON HEALTHCARE Co., Ltd. Matsusaka Factory (9611045)
OMRON HEALTHCARE's Matsusaka Factory has registered product code DXN with the FDA.
SourceMarket signals
Nikkei Asia·Market signals·
BYD earnings, Japanese airline financials, Genting's New York casino tables
BYD reports earnings, impacting the financial landscape in key markets including Asia Pacific.
SourceSafety alerts
FDA Warning Letters·Safety alerts·
FDA Class I: Automated Impella Controller (AIC), used in left heart support blood pump, including the following: 1. Impella Controller, Packaged, AU; Product Code: 0042-0000-AU. 2. Impella Controller, Pack (Abiomed, Inc.)
The FDA issued a Class I recall for the Automated Impella Controller due to detection issues with the Impella pump.
SourceCompetitor moves
Nikkei Asia·Competitor moves·
How security concerns derailed MBK's bid for Japan's Makino Milling
Security concerns halted MBK's acquisition of Makino Milling in Japan due to regulatory issues.
SourceTrack these signals continuously.
MedFlux monitors regulators and medical device market sources across priority countries so regulatory, quality, and strategy teams can review changes without manually checking agency databases.